Table 1

Baseline characteristics of HCC cases and matched controls

CharacteristicHCC cases (N=97 430)Controls* (N=194 860)
Number%Number%
Age (mean ± SE)62.49±0.0462.48±0.03
 20–49 years of age17 55618.0235 17918.02
 50–59 years of age21 23021.7942 43221.79
 60–69 years of age28 15428.9056 41028.90
 70–79 years of age23 32023.9446 49423.94
 ≥80 years of age71707.3614 3457.36
Gender
 Female26 47027.1752 94027.17
 Male70 96072.83141 92072.83
Diabetes patients22 04722.6325 77313.23
 DM duration (year, mean ± SD)3.89±0.023.97±0.02
 DM control (physician visits per year)5.68±0.035.34±0.03
 OHA use (days per year, mean ± SD)
  Metformin105.59±0.82118.66±0.80
  Insulin21.01±0.4312.68±0.32
  Thiazolidinediones9.39±0.2612.23±0.28
  Sulphonylurea and meglitinide159.24±0.90163.69±0.84
  α-Glucosidase inhibitors9.56±0.259.16±0.23
Liver disease
 Hepatitis B24 87725.5344352.28
  Lamivudine* and entecavir35933.6992510.13
 Hepatitis C20 16320.6930951.59
 Alcoholic liver diseases58225.9819080.98
 Liver cirrhosis33903.486580.34
Comorbidity
 Ischaemic heart disease16 72017.1650 14225.73
 Cerebral vascular disease11 97112.2937 20719.09
 Hypertension38 96439.9999 11150.86
 Chronic obstructive lung disease24 21324.8559 25430.41
 Hyperlipidaemia54435.5925 71013.19
 Renal failure56185.7784154.32
  • * Matched by age (±1 years), gender and the date of physician visit.

  • DM, diabetes mellitus; HCC, hepatocellular carcinoma; OHA, oral hypoglycaemic agent.